



## Berkshire West Area Prescribing Committee

<b>Drug Name</b>	Silicone keloid dressings and silicone gels	
<b>Indication under review</b>	Reduction or prevention of hypertrophic and keloid scarring	
<b>Policy No:</b>	APC 061	
<b>Date of Issue/ Date of reissue:</b>	January 2014/ March 2017	
<b>Review Date:</b>	March 2020	
<b>Policy Statement:</b>	Silicone keloid dressings and silicone gels are not recommended for the reduction or prevention of hypertrophic and keloid scarring due to insufficient evidence of efficacy and cost effectiveness.	
<b>Traffic Light Status</b>	<b>Brown</b>	
<b>Key Points considered:</b>	<ul style="list-style-type: none"> <li>• Weak evidence of any benefit of silicon gel as a prevention for abnormal scarring in high risks individuals and the poor quality of research means a great deal of uncertainty prevails.</li> <li>• Not cost effective.</li> <li>• Cosmetic treatments are not routinely funded on the NHS.</li> </ul>	
<b>References:</b>	<ol style="list-style-type: none"> <li>1. O'Brien L, Pandit A. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Review. Jan 25 2006.</li> <li>2. British National Formulary 60. September 2010.</li> </ol>	
<b>Date taken to APC:</b>	1 <sup>st</sup> March 2017	
<b>Date Ratified by MOC on Behalf of the Board:</b>	15 <sup>th</sup> March 2017	

---

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

<b>Brown</b>	<b>Green</b>	<b>Amber</b>	<b>Red</b>
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only